An Extension Trial to Test if TEV-56286 is Effective in Relieving Multiple System Atrophy

- Multiple System Atrophy
- Recruiting

Study Title: An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy

Teva Identifier: TV56286-NDG-20041

ClinicalTrials.gov Identifier: NCT07197866

Study Status: Recruiting

Trial Condition(s): Multiple System Atrophy

Interventions: Drug: TEV-56286

Study Description: The primary objective of the trial is to describe the long-term safety and tolerability of TEV-56286 administered orally for the treatment of adult participants with Multiple System Atrophy (MSA). A secondary objective of the trial is to further describe the safety and tolerability of TEV-56286. The planned total duration of the trial is approximately 100 weeks

Print

Link to ClinicalTrials.gov for participation criteria and map of study locations

Key Participation Requirements

Gender: All

Age group: Adult, Older Adult

Age Range: 30 years and older

Trial Duration: September 30, 2025 - May 17, 2029

Phase: Phase 2

Study Type

Interventional